Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis
Paul Oykhman, Fernando Aleman Paramo, Jean Bousquet, et al.
Journal of Allergy and Clinical Immunology (2021) Vol. 149, Iss. 4, pp. 1286-1295
Open Access | Times Cited: 160

Showing 26-50 of 160 citing articles:

Biologics for allergic and immunologic diseases
Hideaki Morita, Kenji Matsumoto, Hirohisa Saito
Journal of Allergy and Clinical Immunology (2022) Vol. 150, Iss. 4, pp. 766-777
Closed Access | Times Cited: 28
Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1): a multicentre, randomised, double-blind, placebo-controlled phase 2 clinical trial
Yuan Zhang, Bing Yan, Shen Shen, et al.
EClinicalMedicine (2023) Vol. 61, pp. 102076-102076
Open Access | Times Cited: 22
Evaluation of switching or simultaneous use of biologic treatment in patients with severe chronic rhinosinusitis with nasal polyps and severe asthma. Considerations in clinical decision making
Josje Janna Otten, Rik Johannes Leonardus van der Lans, Eugenio De Corso, et al.
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 8, pp. 1041-1049
Open Access | Times Cited: 21
Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: A systematic review of the current knowledge towards an attempt to compare agents’ efficacy
George Papacharalampous, Jannis Constantinidis, G. Fotiadis, et al.
International Forum of Allergy & Rhinology (2023) Vol. 14, Iss. 1, pp. 96-109
Open Access | Times Cited: 21
EUFOREA/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care
Peter W. Hellings, Isam Alobid, Wilma Terezinha Anselmo‐Lima, et al.
Allergy (2023) Vol. 79, Iss. 5, pp. 1123-1133
Open Access | Times Cited: 21
The Management of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With Biologics
A. Wautlet, Claus Bachert, Martin Desrosiers, et al.
The Journal of Allergy and Clinical Immunology In Practice (2023) Vol. 11, Iss. 9, pp. 2642-2651
Closed Access | Times Cited: 17
Interleukin‐5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: Effects on and beyond eosinophils
Kathleen M. Buchheit, Dominick Shaw, Geoffrey Chupp, et al.
Allergy (2024) Vol. 79, Iss. 10, pp. 2662-2679
Open Access | Times Cited: 6
Interpretation of Clinical Efficacy of Biologics in Chronic Rhinosinusitis With Nasal Polyps via Understanding the Local and Systemic Pathomechanisms
Seung Koo Yang, Seong Cho, Dae Woo Kim
Allergy Asthma and Immunology Research (2022) Vol. 14, Iss. 5, pp. 465-465
Open Access | Times Cited: 25
Evaluating enrollment and outcome criteria in trials of biologics for chronic rhinosinusitis with nasal polyps
Larry Borish, Noah Cohen, Geoffrey Chupp, et al.
Annals of Allergy Asthma & Immunology (2022) Vol. 129, Iss. 2, pp. 160-168
Open Access | Times Cited: 23
Nonsteroidal Anti-inflammatory Drug (NSAID) Tolerance After Biological Therapy in Patients With NSAID-Exacerbated Respiratory Disease: A Randomized Comparative Trial
Jorge Sánchez, Elizabeth García, Juan‐Felipe Lopez, et al.
The Journal of Allergy and Clinical Immunology In Practice (2023) Vol. 11, Iss. 7, pp. 2172-2179
Closed Access | Times Cited: 16
Effect of Dupilumab on Type 2 Biomarkers in Chronic Rhinosinusitis With Nasal Polyps: SINUS-52 Study Results
Claus Bachert, Tanya M. Laidlaw, Seong Cho, et al.
Annals of Otology Rhinology & Laryngology (2023) Vol. 132, Iss. 12, pp. 1649-1661
Open Access | Times Cited: 14
Care for Patients with Type-2 Chronic Rhinosinusitis
Gianmarco Giunta, Francesca Pirola, Francesco Giombi, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 4, pp. 618-618
Open Access | Times Cited: 13
Aspirin-exacerbated respiratory disease
Jyotsna Mullur, Kathleen M. Buchheit
Annals of Allergy Asthma & Immunology (2023) Vol. 131, Iss. 3, pp. 317-324
Open Access | Times Cited: 13
Pathogenesis of chronic rhinosinusitis with nasal polyp and a prominent T2 endotype
Said Ahmad Shah, Masayoshi Kobayashi
Heliyon (2023) Vol. 9, Iss. 9, pp. e19249-e19249
Open Access | Times Cited: 13
Brazilian guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps ‒ 2024 update
Wilma Terezinha Anselmo‐Lima, Fabrizio Ricci Romano, Edwin Tamashiro, et al.
Brazilian Journal of Otorhinolaryngology (2024) Vol. 90, Iss. 3, pp. 101394-101394
Open Access | Times Cited: 5
Biologikatherapie bei schwer erkrankten Patienten mit „NSAID-exacerbated respiratory disease“ und stattgehabter ASS‑Desaktivierung
Anna-Rebekka Staufenberg, H. Frankenberger, Ulrike Förster‐Ruhrmann, et al.
HNO (2024) Vol. 72, Iss. 7, pp. 473-483
Open Access | Times Cited: 5
Controversies in Allergy: Aspirin Desensitization or Biologics for Aspirin-Exacerbated Respiratory Disease—How to Choose
Tanya M. Laidlaw, Derek K. Chu, Whitney W. Stevens, et al.
The Journal of Allergy and Clinical Immunology In Practice (2022) Vol. 10, Iss. 6, pp. 1462-1467
Closed Access | Times Cited: 20
A Decade of Clinical Advances in Chronic Rhinosinusitis: 2012–2022
Robert M. Naclerio, Joaquim Mullol, Whitney W. Stevens
The Journal of Allergy and Clinical Immunology In Practice (2023) Vol. 11, Iss. 1, pp. 43-50
Closed Access | Times Cited: 11
Olfactory Loss in Rhinosinusitis: Mechanisms of Loss and Recovery
Agnès Dekeyser, Caroline Huart, Thomas Hummel, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 8, pp. 4460-4460
Open Access | Times Cited: 4
Outcome measures for chronic rhinosinusitis with nasal polyps
Ahmad R. Sedaghat, Raewyn G. Campbell, Richard Douglas, et al.
Rhinology Journal (2024)
Open Access | Times Cited: 4
Leukotriene receptor antagonists as add-on therapy to antihistamines for urticaria: a systematic review and meta-analysis of randomized clinical trials
Daniel Rayner, Ming Liu, Alexandro Chu, et al.
Journal of Allergy and Clinical Immunology (2024)
Open Access | Times Cited: 4
Anti-IL-4Rα monoclonal antibody (CM310) in patients with chronic rhinosinusitis with nasal polyps (CROWNS-2): Rationale and design of a multicenter, randomized, double-blind, placebo-controlled, parallel-group study
Shen Shen, Bing Yan, Ming Wang, et al.
Asia Pacific Allergy (2024) Vol. 14, Iss. 3, pp. 118-123
Open Access | Times Cited: 4
Atopic Dermatitis (Eczema) Guidelines 2023: Highlights
Anna De Benedetto, Mark Boguniewicz, Peck Y. Ong, et al.
The Journal of Allergy and Clinical Immunology In Practice (2024) Vol. 12, Iss. 11, pp. 2955-2965
Closed Access | Times Cited: 4
Oral and intranasal aspirin desensitisation for non-steroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease
Evelijn Lourijsen, Klementina Avdeeva, Kit Liang Gan, et al.
Cochrane library (2025) Vol. 2025, Iss. 1
Closed Access
Biological therapy in Chronic rhinosinusitis with nasal polyps
Zeyi Jin, Bing Yan, Luo Zhang, et al.
Expert Review of Clinical Immunology (2025)
Closed Access

Scroll to top